Optimal initial dose adjustment of warfarin in orthopedic patients

Annals of Pharmacotherapy

Volumn 41, Issue 11, 2007, Pages 1798-1804

  Lenzini, Petra A ^a   Grice, Gloria R ^b   Milligan, Paul E ^a   Gatchel, Susan K ^a   Deych, Elena ^c   Eby, Charles S ^c   Burnett, R Stephen J ^d   Clohisy, John C ^c   Barrack, Robert L ^c   Gage, Brian F ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VANCOUVER ISLAND HEALTH AUTHORITY   (Canada)

Author keywords

Anticoagulants; Orthopedics; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ATORVASTATIN; COTRIMOXAZOLE; DEXTROPROPOXYPHENE; FLUINDOSTATIN; MEVINOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PRAVASTATIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROSUVASTATIN; SIMVASTATIN; STATINE DERIVATIVE; THYROXINE; WARFARIN;

ALGORITHM; ARTICLE; BLEEDING; COHORT ANALYSIS; DRUG DOSE COMPARISON; HUMAN; INTERNATIONAL NORMALIZED RATIO; INTRAOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VALIDATION PROCESS; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BLOOD LOSS, SURGICAL; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; VENOUS THROMBOSIS; WARFARIN;

EID: 35748965297     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K197     Document Type: Article

References (28)

1. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology foundation guide to warfarin therapy. Circulation 2003;107:1692-711.
2. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001;119(1 suppl):22S-38S.
3. Ageno W, Squizzato A, Dentali F, Crowther M. Tailoring warfarin induction doses to reflect individual and disease-specific factors. Am J Med 2005;118:143-4.
4. Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med 2003;138:714-9.
5. Siguret V, Gouin I, Debray M, et al. Initiation of warfarin therapy in elderly medical inpatients: a safe and accurate regimen. Am J Med 2005;118:137-42.
6. Gedge J, Orme S, Hampton KK, Channer KS, Hendra TJ. A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing 2000;29:31-4.
7. Roberts GW, Helboe T, Nielsen CBM, et al. Assessment of an age-adjusted warfarin initiation protocol. Ann Pharmacother 2003;37:799-803. DOI 10.1345/aph.1A372
8. Fennerty A, Dolben J, Thomas P, et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J (Clin Res Ed) 1984;288:1268-70.
9. Cooper MW, Hendra T. Prospective evaluation of a modified Fennerty regimen for anticoagulating elderly people. Age Ageing 1998;27:655-6.
10. Crowther MA, Harrison L, Hirsh J. Warfarin: less may be better - in response (letter). Ann Intern Med 1997;127:333.
11. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133-6.
12. Anderson FA Jr, Hirsh J, White K, Fitzgerald RH Jr. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the hip and knee registry. Chest 2003;124(6 suppl):349S-56S.
13. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-106.
14. Rahman M, BinEsmael TM, Payne N, Butchart EG. Increased sensitivity to warfarin after heart valve replacement. Ann Pharmacother 2006;40:397-401. Epub 28 Feb 2006. DOI 10.1345/aph.1G407
15. Prandoni P, Bruchi O, Sabbion P, et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch Intern Med 2002;162:1966-71.
16. Voora D, Eby C, Linder MW, et al. Prospective dosing of warfarin based on cytochrome p-450 2c9 genotype. Thromb Haemost 2005;93:700-5.
17. Cohen LH, van Leeuwen RE, van Thiel GC, van Pelt JF, Yap SH. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome p450 enzymes. Biopharm Drug Dispos 2000;21:353-64.
18. Millican E, Lenzini P, Milligan P, et al. Genetic-based dosing in orthopaedic patients beginning warfarin therapy. Blood 2007;110:1511-5.
19. Roberts GW, Druskeit T, Jorgensen LE, et al. Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty's protocol. Aust N Z J Med 1999;29:731-6.
20. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 2005;127:2049-56.
21. Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006;16:101-10.
22. Lee SC, Ng SS, Oldenburg J, et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 2006;79:197-205.
23. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA. Functional characterization of novel allelic variants of cyp2c9 recently discovered in Southeast Asians. J Pharmacol Exp Ther 2005;315:1085-90.
24. Sconce EA, Khan TI, Daly AK, Wynne HA, Kamali F. The impact of simvastatin on warfarin disposition and dose requirements. J Thromb Haemost 2006;4:1422-4.
25. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005;106:2329-33.
26. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 2005;5:262-70.
27. Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999;159:46-8.
28. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004;91:87-94.